PTPN11 and neoplasm: To evaluate the potential of SHP2 inhibitor across tumor types, we screened 922 cancer cell lines of diverse origin with SHP099 at 9 different doses (maximum dose, 10.24 μM; lowest, 40 nM); we also concomitantly (same screen campaign) profiled trametinib and the ERK inhibitor VX11E.